Document ID: chunk:federal_register_of_legislation:F2024L00217:reg:9:p2
Version: federal_register_of_legislation:F2024L00217
Segment Type: reg
Provision Reference: reg 9 (pt 2/3)
Character Range: 7127–10270

of 5 years before clinical onset; and
(b)          where the first exposure in that period occurred at least 2 years before clinical onset;
Note: being exposed to benzene as specified is defined in the Schedule 1 – Dictionary.
(9)          inhaling, ingesting or having cutaneous contact with benzene:
(a)          in an amount greater than 5 ppm-years of cumulative exposure before clinical onset; and
(b)          where the first exposure occurred at least 2  years before clinical onset;
Note: ppm-years is defined in the Schedule 1 - Dictionary.
(10)      being obese for at least 5 years within the 20 years before clinical onset;
Note: being obese is defined in the Schedule 1 - Dictionary.
(11)      undergoing organ or haematopoietic stem cell transplantation, excluding corneal transplant, before the clinical onset;
(12)      having infection with human immunodeficiency virus before clinical onset;
(13)      inhaling formaldehyde:
(a)          for a cumulative total of at least 5,000 hours within a continuous period of 10 years before the clinical onset of acute myeloid leukaemia; and
(b)          where the first exposure in that period occurred at least 5 years before the clinical onset of acute myeloid leukaemia;
Note: inhaling formaldehyde is defined in the Schedule 1 – Dictionary.
(14)      having one of the following autoimmune diseases before clinical onset:
(a)          autoimmune haemolytic anaemia;
(b)          giant cell arteritis;
(c)          pernicious anaemia;
(d)          polymyalgia rheumatica;
(e)          rheumatoid arthritis;
(f)           sarcoidosis;
(g)          systemic lupus erythematosus;
(h)          systemic vasculitis; or
(i)            ulcerative colitis.
(15)      inhaling, ingesting or having cutaneous contact with one of the following pesticides for a cumulative period of at least 1,000 hours before the clinical onset of acute myeloid leukaemia, where the first exposure occurred at least 5 years before clinical onset:
(a)          aldrin;
(b)          dieldrin;
(c)          diazinon;
(d)          chlordane; or
(e)          heptachlor.
(16)      inhaling styrene:
(a)          for a cumulative total of at least 2,500 hours within a continuous period of 5 years before the clinical onset of acute myeloid leukaemia; and
(b)          where the first exposure in that period occurred at least 5 years before the clinical onset of acute myeloid leukaemia;
Note 1: Inhalation of styrene can occur in the manufacture of fibreglass-reinforced plastic products, in the production of styrene, polystyrene, and styrene-based plastics and rubbers, and in the use of products containing styrene, such as paints, adhesives, metal cleaners, and varnishes.
Note 2: inhaling styrene is defined in the Schedule 1 - Dictionary.
(17)      being exposed to styrene:
(a)          in an amount greater than 10 ppm-years of cumulative exposure before the clinical onset of acute myeloid leukaemia; and
(b)          where the first exposure occurred at least 5 years before the clinical onset of acute myeloid leukaemia;
Note: ppm-years is defined in the Schedule 1 - Dictionary
(18)      inability to